- Mabion S.A. has entered into a loan agreement of up to €3.1 million with CBC Co., Ltd. to support liquidity during its strategic transformation period.
- The financing will be provided in two tranches over three years and includes an option allowing the lender to convert the debt into company shares.
Mabion S.A. has signed a loan agreement with CBC Co., Ltd., a Tokyo-based company, for financing of up to €3.1 million to support the company’s liquidity during its strategic transformation and implementation of its 2025–2030 business plan. Mabion operates as a biologics-focused CDMO providing development and contract manufacturing services.
The financing will be provided in two equal tranches with a three-year term from the date of disbursement. The loan carries an initial interest rate of 10.53% per year. If the company’s General Meeting approves a resolution allowing debt-to-equity conversion, the rate will change to the National Bank of Poland reference rate plus a margin of two percentage points.
The agreement includes an option allowing the lender to convert all or part of the loan and accrued interest into Mabion shares at any time upon request. The conversion price would be based on the company’s market share price at the time of the agreement, with a 20% discount, or aligned with the share price offered to other investors in the event of a share issuance. The financing is secured through a mortgage on Mabion’s real estate and a registered pledge on key production assets, including bioreactors and manufacturing lines.
“Obtaining financing from CBC Co., Ltd. strengthens our financial liquidity and provides additional flexibility in the implementation of Mabion’s strategic goals.”
Gregor Kawaletz, CEO of Mabion S.A.
According to the company, the agreement forms part of broader efforts to maintain operational stability while pursuing new CDMO contracts. Mabion previously secured additional bridge financing, including up to PLN 18 million from Twiti Investments in October 2025 and up to PLN 6 million from ACRX Investments in February 2026, as it continues discussions with global partners on future projects.
